Amgen’s collaboration with BeiGene and Biogen’s partnership with C4 Therapeutics were some crucial alliances last year. ![]() Strategic collaborations also surfaced as major game changers for the industry. This also makes these biotech firms more visible for collaborations and acquisitions. By going public, a significant portion of this much-required financing is taken care of. This is because biotech companies require significant financing, particularly as they advance their research. Biotech IPOs have been increasing steadily over the past few years. Second, the number of initial public offerings was also considerable. Bristol-Myers Squibb’s acquisition of Celgene Corporation and Eli Lilly and Company’s acquisition of Loxo Oncology were some of the major deals that took place last year. The industry made headlines since the beginning of 2019, thanks to numerous mergers and acquisitions, and initial public offerings that kept the space in investors’ focus. ![]() What’s more, the products and services offered by the industry are always in demand because of their nature, which makes biotech a lucrative investment space irrespective of market conditions. The biotechnology industry witnessed remarkable growth last year, owing to a series of mergers and acquisitions, initial public offerings, collaborative operations and new job additions in the space that boosted it throughout 2019.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |